Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines stock forecast 2026–2028What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Revolution Medicines is 253.47, 47.1% above the current price of 172.28. Their targets range from 179.00 to 320.00.
Of the 18 firms that rated Revolution Medicines in the past 12 months, 17 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
12-month price target
253.47 USD
+47.13%
Analysts' 1-year price targets range from 179.00 to 320.00, with an average of 253.47.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
18 ratings
| Buy | 17 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 320.00 |
| Average target | 253.47 |
| Lowest target | 179.00 |
| Current price | 172.28 |
Revolution Medicines price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Revolution Medicines price target and rating?
See how analysts moved their price target
How analysts rate Revolution Medicines, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
17 of 18 firms rate it buy now, against 11 of 11 in December 2025.
Buy Hold Sell
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Revolution Medicines analyst upgrades, downgrades and price targets
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 19 Oct 2026 | Truist Financial | Reiterated · Buy | 240.00 → 241.00 | +0.4% | 177.96 |
| 14 Oct 2026 | RBC Capital | Reiterated · Outperform | 259.00 → 260.00 | +0.4% | 194.78 |
| 8 Oct 2026 | RBC Capital | Reiterated · Outperform | 251.00 → 259.00 | +3.2% | 183.52 |
| 7 Oct 2026 | Truist Financial Gregory Renza | Reiterated · Buy | 231.00 → 240.00 | +3.9% | 201.65 |
| 28 Sept 2026 | Loop Capital Markets Leah Rush Cann | — | 318.00 | — | 204.97 |
| 24 Sept 2026 | Goldman Sachs | — | 73.00 → 267.00 | +265.8% | 190.74 |
| 10 Sept 2026 | Morgan Stanley Sean Laaman | — | 255.00 | — | 207.68 |
| 9 Sept 2026 | Stifel Nicolaus Laura Prendergast | Reiterated · Buy | 85.00 → 230.00 | +170.6% | 207.32 |
| 31 Aug 2026 | Needham | Reiterated · Buy | 235.00 → 275.00 | +17.0% | 207.88 |
| 28 Aug 2026 | UBS | Reiterated · Buy | 175.00 → 265.00 | +51.4% | 221.15 |
| 28 Aug 2026 | Guggenheim | Reiterated · Buy | 240.00 → 275.00 | +14.6% | 221.15 |
| 27 Aug 2026 | RBC Capital Leonid Timashev | Reiterated · Outperform | 203.00 → 251.00 | +23.6% | 220.82 |
| 27 Aug 2026 | Raymond James Sean McCutcheon | — | 76.00 → 248.00 | +226.3% | 220.40 |
| 27 Aug 2026 | Evercore ISI | Reiterated · Outperform | 230.00 → 320.00 | +39.1% | 215.44 |
| 27 Aug 2026 | H.C. Wainwright Robert Burns | — | 195.00 → 280.00 | +43.6% | 215.44 |
| 26 Aug 2026 | Oppenheimer | — | 230.00 → 260.00 | +13.0% | 215.44 |
| 21 Aug 2026 | Bernstein Jeffrey Walch | Reiterated · Market Perform | 151.00 → 179.00 | +18.5% | 211.74 |
| 11 Aug 2026 | Truist Financial | Reiterated · Buy | 210.00 → 231.00 | +10.0% | 205.19 |
| 10 Aug 2026 | Wolfe Research Kalpit Patel | — | 220.00 | — | 205.74 |
| 6 Aug 2026 | Evercore ISI | Reiterated · Outperform | 200.00 → 230.00 | +15.0% | 201.19 |
| 6 Aug 2026 | Wedbush | Reiterated · Outperform | 192.10 → 201.00 | +4.6% | 201.90 |
| 6 Aug 2026 | Oppenheimer | — | 195.00 → 230.00 | +17.9% | 200.65 |
| 6 Aug 2026 | RBC Capital | Reiterated · Outperform | 182.00 → 203.00 | +11.5% | 197.30 |
| 6 Aug 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 235.00 → 240.00 | +2.1% | 197.30 |
| 23 Jul 2026 | Wedbush Robert Driscoll | Reiterated · Outperform | 181.00 → 192.10 | +6.1% | 190.94 |
| 9 Jul 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 205.00 → 235.00 | +14.6% | 189.77 |
| 6 Jul 2026 | Mizuho Securities | Reiterated · Outperform | 143.00 → 215.00 | +50.3% | 190.50 |
| 2 Jul 2026 | Wedbush | Reiterated · Outperform | 147.00 → 181.00 | +23.1% | 184.29 |
| 30 Jun 2026 | Truist Financial | Reiterated · Buy | 179.00 → 210.00 | +17.3% | 192.62 |
| 29 Jun 2026 | Needham Ami Fadia | Reiterated · Buy | 235.00 | — | 186.39 |
| 9 Jun 2026 | UBS Michael Yee | — | 170.00 → 175.00 | +2.9% | 148.45 |
| 2 Jun 2026 | RBC Capital Leonid Timashev | Reiterated · Outperform | 162.00 → 182.00 | +12.3% | 163.68 |
| 1 Jun 2026 | H.C. Wainwright | — | 169.00 → 195.00 | +15.4% | 162.51 |
| 1 Jun 2026 | Oppenheimer | Reiterated · Outperform | 165.00 → 195.00 | +18.2% | 157.48 |
| 21 May 2026 | Bernstein Jeffrey Walch | — | 151.00 | — | 153.73 |
| 18 May 2026 | Truist Financial | — | 99.00 → 179.00 | +80.8% | 145.66 |
| 7 May 2026 | Guggenheim | Reiterated · Buy | 175.00 → 205.00 | +17.1% | 151.07 |
| 14 Apr 2026 | Guggenheim | Reiterated · Buy | 160.00 → 175.00 | +9.4% | 136.30 |
| 14 Apr 2026 | Evercore ISI | Reiterated · Outperform | 200.00 | — | 136.30 |
| 14 Apr 2026 | RBC Capital | Reiterated · Outperform | 140.00 → 162.00 | +15.7% | 136.30 |
| 14 Apr 2026 | H.C. Wainwright Robert Burns | — | 72.00 → 169.00 | +134.7% | 136.30 |
| 13 Apr 2026 | Oppenheimer | Reiterated · Outperform | 150.00 → 165.00 | +10.0% | 134.88 |
| 26 Feb 2026 | Wells Fargo Eva Fortea Verdejo | Reiterated · Overweight | 144.00 | — | 103.24 |
| 27 Jan 2026 | Oppenheimer Jay Olson | Reiterated · Outperform | 150.00 | — | 97.78 |
| 22 Jan 2026 | UBS | — | 170.00 | — | 117.85 |
| 21 Jan 2026 | RBC Capital Leonid Timashev | Reiterated · Outperform | 77.00 → 140.00 | +81.8% | 116.22 |
| 20 Jan 2026 | Guggenheim | Reiterated · Buy | 160.00 | — | 120.28 |
| 13 Jan 2026 | Goldman Sachs Andrea Newkirk | — | 73.00 | — | 119.95 |
| 13 Jan 2026 | Mizuho Securities | Reiterated · Outperform | 143.00 | — | 117.17 |
| 9 Jan 2026 | Wedbush | Reiterated · Outperform | 147.00 | — | 112.68 |
Revolution Medicines EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
ReportedEstimate
EPS
ReportedEstimate
Does Revolution Medicines beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 16.6% off the result, either way, and their revenue estimate 341.9%, over the last 12 quarters.
- EPS beats
- 6 / 28
- Revenue beats
- 12 / 16
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- -12.2%
- Since
- March 2020
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | -2.35 | -1.90 | +19.1% | 25.58M | 197.60M | +672.4% |
| Q2 FY2026 | 5 Aug 2026 | -2.04 | -3.06 | -50.0% | 1.77M | — | — |
| Q1 FY2026 | 6 May 2026 | -1.84 | -2.29 | -24.5% | 2.43M | — | — |
| Q4 FY2025 | 25 Feb 2026 | -1.58 | -1.86 | -17.7% | 3.68M | — | — |
| Q3 FY2025 | 5 Nov 2025 | -1.42 | -1.61 | -13.4% | 1.69M | — | — |
| Q2 FY2025 | 6 Aug 2025 | -1.14 | -1.31 | -15.1% | 27.53M | — | — |
| Q1 FY2025 | 7 May 2025 | -1.12 | -1.13 | -0.9% | 1.20M | — | — |
| Q4 FY2024 | 26 Feb 2025 | -1.01 | -1.12 | -10.9% | 375.00K | — | — |
| Q3 FY2024 | 6 Nov 2024 | -0.89 | -0.94 | -5.6% | 346.15K | — | — |
| Q2 FY2024 | 7 Aug 2024 | -0.77 | -0.81 | -5.2% | 807.69K | — | — |
| Q1 FY2024 | 8 May 2024 | -0.75 | -0.70 | +6.7% | 1.37M | — | — |
| Q4 FY2023 | 26 Feb 2024 | -0.88 | -1.14 | -29.5% | 666.67K | 742.00K | +11.3% |
Revolution Medicines stock price 2026–2028: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
There are no price scenarios for Revolution Medicines: its P/E has been above 60, or from losses, too often in the last five years to price its earnings at, and similar companies' P/Es put its value too far from its price to stand in. The earnings analysts expect are in the estimates above.
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.